The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
GILT study: Oral vinorelbine (NVBo) and cisplatin (P) with concomitant radiotherapy (RT) followed by either consolidation (C) with NVBo plus P plus best supportive care (BSC) or BSC alone in stage (st) III non-small cell lung cancer (NSCLC): Final results of a phase (ph) III study.
Rudolf M. Huber
Research Funding - Pierre Fabre Medicament
Walburga Engel-Riedel
No relevant relationships to disclose
Jens Kollmeier
Consultant or Advisory Role - Boehringer Ingelheim (U); Lilly (U); Roche (U)
Stefan Andreas
Honoraria - Roche
Susanne Staar
No relevant relationships to disclose
Gunther Klautke
No relevant relationships to disclose
Rainer Fietkau
Consultant or Advisory Role - Pierre Fabre Medicament
Honoraria - Pierre Fabre Medicament
Research Funding - Pierre Fabre Medicament
Expert Testimony - Pierre Fabre Medicament (U)
Nathalie Vaissiere
Employment or Leadership Position - Pierre Fabre Medicament
Susanne Osowski
Employment or Leadership Position - Pierre Fabre Medicament
Stock Ownership - Pierre Fabre Medicament
Michael Flentje
No relevant relationships to disclose